Irans Healthcare Market on the Rise
Iran’s healthcare industry is set for a bright future. The country is ranked 15th among Middle East and Africa (MEA) countries in terms of long-term investment potential. With a population of 75 million people — more than 50% of which is under the age of 35 — and an enormous amount of wealth coming in from its oil & gas reservoirs, Iran’s GDP is expected to grow at an average of 2.4% during the next 10 years.
Iran also ranks well for Industry Rewards due to its population and healthcare reforms. The huge youth population cohort coupled with the healthcare industry’s room for improvement, promise growth in the private sector and investments in the pharmaceutical, healthcare facilities, and medical devices market.
Iran’s healthcare industry was worth 26.44 billion USD in 2011, growing to 28.13 bilion USD (+6.4%) in 2012. Currently, healthcare out-of-pocket (OOP) expenditure is at 55% — very high compared with neighbouring countries. Cardiovascular diseases account for 45% of deaths, whereas 18% are a result of road accidents, which also account for high disabilities and injuries numbers, especially among the younger population. The third main cause of death is cancer (14%, particularly lung cancer, expected to increase to 18% by 2030), followed by neonatal and respiratory diseases (6%). Diabetes, osteoporosis, and nutritional and psychological disorders are also on the rise. Drug addiction problems affect 3–5% of the population, with a strong correlation to HIV/AIDS cases. The need for a better medical system and products to address Iran’s healthcare issues would therefore favour investments in the country.
Iran’s pharmaceutical market was worth 3.51 billion USD in 2012, with a projected 13% compound annual growth rate (CAGR) until 2014, beyond which it will steady at 8%. Expenditure on pharmaceuticals is expected to reach 4.14 billion USD by 2019 at a CAGR of 11%, taking inflation into account. The country produces 90% of its medicines and the Ministry of Health has put an ambitious goal of self-sufficiency within 4 years time.
Local production is mainly focused on generic medicines, with more than 70 Iranian pharmaceutical companies producing generics. On the other hand, Iran’s shortage of specialized medicine has opened up the doors for Indian and Chinese products. “These lack quality and usually present side-effects, highlighting the market need for high volumes of specialized medicine, preferably of European and American origin,” notes Frost & Sullivan Healthcare Analyst Uldouz Berenjforoush. “The country is expected to turn towards high volumes of foreign imports of high quality medicines for now.”
The country’s medical devices industry is import-driven and was worth 964 million USD in 2012. Government healthcare investments towards modernization of services and facilities have been weighty. While the private sector accounts for 10% of hospital beds, which is rapidly growing, private expenditures account only for 20% of total expenditure. Nearly 88% of the country’s medical devices are imported. Of this, 70.4% is from the European Union, mainly Germany, the Netherlands and the UK. Continued growth is expected in the medical devices sector in order to address the shortage of specialized devices. This market is estimated to reach 1053 million USD by 2017.
Following the 1990 Iraq–Iran war, Iran’s government saw the need for reforms, focused on increasing the number of personnel, hospital beds, facilities as well as improving services and infrastructure, in an effort to attract and increase foreign investments. In 2012, the physician to population ratio had come to 1 doctor per 845 people — a large improvement from 10 years ago (1/3120) — and more than 90% of the population has access to healthcare services. The government provides the majority of health insurance, although in 2001 the law was passed to allow the establishment of private insurance systems. The military, the National Oil Company and Bank Melli have their own high-quality hospitals, while wealthier Iranians enjoy better quality private hospitals. “Private facilities are becoming more and more attractive due to the lack of efficiency in the public healthcare sector, with long waiting lines and poor facilities,” says Berenjforoush. “The industry is still very young in the country, and there is a considerable room for growth in this field.”
Medical tourism has been flourishing in Iran as it offers quality expertise at lower costs. In 2012 alone, the country hosted over 200,000 health tourists, who brought over 1.5bn USD to Iran, twice as much as the numbers in 2011. In the first half of 2013, over 85,670 medical tourists have visited Iran, increasing the total number from last year by 135%. Health tourists come mainly from Azerbaijan, Turkmenistan, Iraq, Turkey, Kuwait, Oman, India and Pakistan, and the majority of visits are for transplant, ophthalmology, orthopaedic, and dentistry purposes. The Iranian government has recognized the opportunities in medical tourism, investing in infrastructure to better serve visitors. For instance, medical services for Azerbaijani tourists are provided nearer the border. There are also taxi services available to take medical tourists from the border to the appropriate healthcare facility. Iran is focusing to become the hub for medical tourism of the Muslim world, especially serving patients from the Gulf countries.
Iran’s post-war healthcare industry has been rapidly improving although sanctions have had an impact on market growth. Nonetheless, the country is striving to stand out amongst its competitors by aiming to provide high quality services to Iranians as well as medical tourists. With a high OOP and growing population as well as its goal to be the hub for medical tourism in the Muslim world, Iran opens up the doors to private investments, especially in the medical devices sector and specialized medicines.
If you are interested in more information on this Market Insight — Iran’s Healthcare Market, please send an email to Anna Zanchi, Corporate Communications, at [email protected]
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance